Over at bbgm, Deepak Singh considers a slide that's been circulating which compares the number of approved New Molecular Entities to spending by members of PhRMA from 1970 to the early 2000s. Paul Kedrosky, who presented the slide recently, notes that "the mapping of the genome, and other such inflection points in this failure-prone industry, has done nothing to accelerate [new] drugs, while causing costs to escalate dramatically."